investing.comNov 10$LEGN

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

Original reporting

investing.com

Published Nov 10, 2026, 1:48 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 10, 2026, 1:55 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$LEGN

Bearish

high confidence

Mentioned

$LEGN

Relevance

7/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$LEGNBearishHigh

Why it matters

The earnings miss caused a sharp pre‑market decline, highlighting profitability concerns despite pipeline progress.

Market read

Immediate price impact for LEGN; broader biotech sentiment may soften.

What to watch

New CEO appointment and FDA IND clearance for LB2501 may provide longer‑term upside.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Legend Biotech reported Q3 2026 results ahead of market open, missing EPS expectations but beating revenue forecasts.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$LEGNBearishHigh confidence

Context

Q3 2026 earnings miss: GAAP loss of $0.13 vs breakeven expectations, driving a 13.2% pre‑market slide.

Expected impact

likely further downside as investors price in weaker profitability.

Evidence & confidence

The surprise loss and weak guidance outweigh revenue beat, and technicals are bearish.

Market effects

Sector

Biotech sector may face broader pressure as high‑beta names react to earnings disappointment.

Regional

NASDAQ drag contributes to overall market weakness.

Global

Limited to US biotech investors.

Counterpoint

What could challenge this read

Revenue beat and CARVYKTI sales growth could support a rebound if guidance improves.

Key entities

Company
Legend Biotech Corp
Biotech firm listed on NASDAQ under ticker LEGN.

Read at source ← All news

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

finance.yahoo.comNov 10

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.

investing.comNov 10

$LEGNHigh

Legend Biotech Corp (LEGN): Financial results for Q3 2026

Legend Biotech Corp (LEGN) furnished an SEC Form 6-K — earnings release. Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights • CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million • Half of CARTITUDE-2 Cohort A patients remained alive and progress

SEC EDGAR 6-KNov 10

MedAI 9/10

Legend Biotech Corporation Reports 100% Response Rates in 8 LB2501 Patients

Legend Biotech reported 100% response rates in 8 patients treated with LB2501 at dose level 2, with responses lasting up to 5 months. The data was presented in abstracts for the ASH 2026 conference, showing a CITADEL IEC-parkinsonism rate of 1.6% with preemptive steroids. The next catalyst is the full ASH 2026 presentations, including more Phase 1 data for LB2501 and LUCAR-G39D.

tradingview.comNov 4

$LEGNHighAI 8/10

Did Five Year CARVYKTI Data Just Shift Legend Biotech's (LEGN) Investment Narrative?

Legend Biotech (LEGN) reported five-year data from the CARTITUDE-2 trial, showing 50% of relapsed or refractory multiple myeloma patients alive and progression-free without maintenance after a single CARVYKTI infusion. The results strengthen CARVYKTI's clinical staying power and potential treatment positioning. The company reported a net loss of $91.5 million on $1.27 billion revenue, with analysts projecting 19.0% yearly revenue growth and a shift to positive net income by 2029.

simplywall.stOct 2

$LEGNMedAI 8/10

Legend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myeloma

Legend Biotech (LEGN) reported five-year data from CARTITUDE-2 showing 50% of patients with earlier-line multiple myeloma remained progression-free after a single CARVYKTI infusion. The study, presented at the 2026 IMS Annual Meeting, showed a 69.2% overall survival rate, reinforcing CARVYKTI's potential for durable remission. CARVYKTI is a BCMA-directed cell therapy developed in collaboration with Janssen Biotech.

quiverquant.comSep 25